aurinia pharmaceuticals inc. - AUPH
AUPH
Close Chg Chg %
14.26 0.18 1.26%
Closed Market
14.44
+0.18 (1.26%)
Volume: 886.70K
Last Updated:
Feb 6, 2026, 4:00 PM EDT
Company Overview: aurinia pharmaceuticals inc. - AUPH
AUPH Key Data
| Open $14.26 | Day Range 14.20 - 14.54 |
| 52 Week Range 6.56 - 16.54 | Market Cap $1.92B |
| Shares Outstanding 131.84M | Public Float 116.14M |
| Beta 1.51 | Rev. Per Employee N/A |
| P/E Ratio 25.41 | EPS $0.58 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.00M |
AUPH Performance
| 1 Week | -1.86% | ||
| 1 Month | -5.87% | ||
| 3 Months | -2.40% | ||
| 1 Year | 78.03% | ||
| 5 Years | -8.12% |
AUPH Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
An error occurred while fetching the data.
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Aurinia Pharmaceuticals Inc. - AUPH
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 45.61M | 134.03M | 175.51M | 235.13M | |
Sales Growth
| -9.00% | +193.89% | +30.95% | +33.97% | |
Cost of Goods Sold (COGS) incl D&A
| 3.19M | 5.66M | 14.15M | 28.25M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 2.76M | 2.71M | 11.65M | 19.45M | |
Depreciation
| 663.00K | 629.00K | 606.00K | 600.00K | |
Amortization of Intangibles
| 2.10M | 2.08M | 11.04M | 18.85M | |
COGS Growth
| - | +77.61% | +149.79% | +99.66% | |
Gross Income
| 42.42M | 128.37M | 161.37M | 206.89M | |
Gross Income Growth
| - | +202.64% | +25.71% | +28.21% | |
Gross Profit Margin
| +93.01% | +95.77% | +91.94% | +87.99% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 222.58M | 241.36M | 244.68M | 192.81M | |
Research & Development
| 51.14M | 44.99M | 49.64M | 20.79M | |
Other SG&A
| 171.44M | 196.37M | 195.04M | 172.03M | |
SGA Growth
| +52.21% | +8.44% | +1.37% | -21.20% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 23.11M | - |
EBIT after Unusual Expense
| (180.16M) | (112.99M) | (83.31M) | (9.03M) | |
Non Operating Income/Expense
| (45.00K) | 6.64M | 8.62M | 21.32M | |
Non-Operating Interest Income
| 529.00K | 5.12M | 17.00M | 16.97M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 2.78M | 4.84M | - |
Interest Expense Growth
| - | - | - | +74.23% | - |
Gross Interest Expense
| - | - | 2.78M | 4.84M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (180.21M) | (106.35M) | (77.47M) | 7.45M | |
Pretax Income Growth
| -75.34% | +40.98% | +27.16% | +109.61% | |
Pretax Margin
| -395.15% | -79.35% | -44.14% | +3.17% | |
Income Tax
| 760.00K | 1.83M | 551.00K | 1.70M | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| 760.00K | 1.83M | 551.00K | 1.70M | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (180.97M) | (108.18M) | (78.02M) | 5.75M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (180.97M) | (108.18M) | (78.02M) | 5.75M | |
Net Income Growth
| -76.24% | +40.22% | +27.88% | +107.37% | |
Net Margin Growth
| -396.81% | -80.71% | -44.45% | +2.45% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (180.97M) | (108.18M) | (78.02M) | 5.75M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (180.97M) | (108.18M) | (78.02M) | 5.75M | |
EPS (Basic)
| -1.3988 | -0.7623 | -0.5447 | 0.0402 | |
EPS (Basic) Growth
| -61.39% | +45.50% | +28.55% | +107.38% | |
Basic Shares Outstanding
| 129.37M | 141.91M | 143.24M | 143.06M | |
EPS (Diluted)
| -1.3988 | -0.7623 | -0.5447 | 0.0393 | |
EPS (Diluted) Growth
| -61.39% | +45.50% | +28.55% | +107.21% | |
Diluted Shares Outstanding
| 129.37M | 141.91M | 143.24M | 146.19M | |
EBITDA
| (177.40M) | (110.29M) | (71.67M) | 33.52M | |
EBITDA Growth
| -84.58% | +37.83% | +35.02% | +146.77% | |
EBITDA Margin
| -388.99% | -82.29% | -40.83% | +14.25% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 16.714 | |
| Number of Ratings | 7 | Current Quarters Estimate | 0.193 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 0.935 | |
| Last Quarter’s Earnings | 0.21 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.782 | Next Fiscal Year Estimate | 1.05 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 6 | 4 |
| Mean Estimate | 0.19 | 0.20 | 0.94 | 1.05 |
| High Estimates | 0.22 | 0.25 | 1.33 | 1.70 |
| Low Estimate | 0.18 | 0.17 | 0.64 | 0.45 |
| Coefficient of Variance | 11.95 | 20.48 | 25.44 | 50.55 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Aurinia Pharmaceuticals Inc. - AUPH
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Aurinia Pharmaceuticals Inc. - AUPH
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 21, 2025 | Aurinia Pharmaceuticals, Inc. | 49,364 | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $8.15 per share | 402,316.60 |
| May 21, 2025 | Aurinia Pharmaceuticals, Inc. | N/A | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $8.15 per share | 0.00 |
| May 21, 2025 | Aurinia Pharmaceuticals, Inc. | N/A | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $7.91 per share | 0.00 |
| May 21, 2025 | Aurinia Pharmaceuticals, Inc. | N/A | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $8.16 per share | 0.00 |
| May 21, 2025 | Aurinia Pharmaceuticals, Inc. | N/A | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $7.77 per share | 0.00 |
| May 21, 2025 | Aurinia Pharmaceuticals, Inc. | 98,678 | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $7.94 per share | 783,503.32 |
| May 21, 2025 | Aurinia Pharmaceuticals, Inc. | 50,355 | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $7.91 per share | 398,308.05 |
| May 21, 2025 | Aurinia Pharmaceuticals, Inc. | N/A | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $7.94 per share | 0.00 |
| May 21, 2025 | Aurinia Pharmaceuticals, Inc. | 98,843 | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $7.77 per share | 768,010.11 |
| May 21, 2025 | Aurinia Pharmaceuticals, Inc. | 49,421 | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $8.16 per share | 403,275.36 |
| Mar 7, 2025 | Peter S. Greenleaf | 885,964 | Exercise of rights | 7,016,834.88 |
| Mar 7, 2025 | Greg Keenan | 88,698 | Exercise of rights | 709,584.00 |
| Mar 7, 2025 | Matthew Maxwell Donley | 193,120 | Exercise of rights | 0.00 |
| Mar 7, 2025 | Matthew Maxwell Donley | 154,894 | Acquisition or disposition under a purchase/ownership plan | 0.00 |
| Mar 7, 2025 | Peter S. Greenleaf | 663,495 | Exercise of rights | 5,254,880.40 |
| Mar 7, 2025 | Peter S. Greenleaf | 457,581 | Exercise of rights | 3,660,648.00 |
| Mar 7, 2025 | Peter S. Greenleaf | 624,433 | Grant of rights | 0.00 |
| Mar 7, 2025 | Peter S. Greenleaf | 3,807,961 | Grant of options | 28,750,105.55 |
| Mar 7, 2025 | Peter S. Greenleaf | 667,869 | Exercise of rights | 0.00 |
| Mar 7, 2025 | Peter S. Greenleaf | 506,267 | Exercise of rights | 0.00 |